What is HC Wainwright’s Estimate for MLTX FY2027 Earnings?

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities research analysts at HC Wainwright issued their FY2027 EPS estimates for MoonLake Immunotherapeutics in a research note issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($3.11) for the year. HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, hitting the consensus estimate of ($0.92). During the same quarter in the prior year, the company earned ($0.72) EPS.

A number of other research firms have also weighed in on MLTX. Zacks Research upgraded MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. The Goldman Sachs Group cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and raised their price objective for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. Oppenheimer lifted their price objective on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. Royal Bank Of Canada upped their target price on shares of MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a research note on Monday. Finally, Needham & Company LLC raised their price target on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $27.85.

MoonLake Immunotherapeutics Price Performance

MLTX stock opened at $17.69 on Wednesday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 9.27 and a current ratio of 9.27. The business has a 50-day simple moving average of $15.80 and a two-hundred day simple moving average of $22.31. The company has a market capitalization of $1.14 billion, a P/E ratio of -5.03 and a beta of 1.20. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MLTX. Cormorant Asset Management LP raised its holdings in shares of MoonLake Immunotherapeutics by 118.4% in the 4th quarter. Cormorant Asset Management LP now owns 4,355,433 shares of the company’s stock worth $57,405,000 after purchasing an additional 2,361,260 shares during the period. Janus Henderson Group PLC increased its position in MoonLake Immunotherapeutics by 18,782.8% in the fourth quarter. Janus Henderson Group PLC now owns 2,095,988 shares of the company’s stock worth $27,657,000 after buying an additional 2,084,888 shares during the last quarter. Logos Global Management LP bought a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at $23,065,000. Vivo Capital LLC bought a new stake in shares of MoonLake Immunotherapeutics in the fourth quarter valued at $13,180,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter valued at $6,922,000. 93.85% of the stock is owned by institutional investors.

Insider Buying and Selling at MoonLake Immunotherapeutics

In related news, insider Kristian Reich sold 72,908 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $14.43, for a total transaction of $1,052,062.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Da Silva Jorge Santos sold 70,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the completion of the sale, the chief executive officer directly owned 2,878,577 shares in the company, valued at approximately $41,710,580.73. This represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 402,908 shares of company stock valued at $5,987,162. Insiders own 12.05% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.